Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

2013

Obstetrics and Gynecology

Time Factors

Mark K. Santillan

Articles 1 - 1 of 1

Full-Text Articles in Medicine and Health Sciences

The Effect Of A Novel Glycoprotein Iib/Iiia Antagonist, Sr 121566a, On Platelet Aggregation And Activation In Rhesus Monkeys., Mark Santillan, J. Herring, D. Hoppensteadt, W. Jeske, J. Herbert, J. Fareed Mar 2013

The Effect Of A Novel Glycoprotein Iib/Iiia Antagonist, Sr 121566a, On Platelet Aggregation And Activation In Rhesus Monkeys., Mark Santillan, J. Herring, D. Hoppensteadt, W. Jeske, J. Herbert, J. Fareed

Mark K. Santillan

SR 121566A represents a peptidomimetic glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitor 3-[N- 4-[4-(aminoiminomethyl)phenyl]-1,3-thiazol-2-yl ) -N-(1-carboxymethylpiperid-4-yl) amino] propionic acid, trihydrochloride. To investigate the intravenous and subcutaneous pharmacodynamics of this agent, a primate model ( Macaca mulatta) was used. The IC50 for adenosine diphosphate (ADP) (10 micromol/L)-induced platelet aggregation in this primate platelet system was found to be 45 +/- 6 nmol/L. Comparatively in the human platelet rich plasma system, SR 121566A demonstrated an IC50 of 39 +/- 4 nmol/L. Graded doses of SR 121566A in the range of 25-400 microg/kg were administered intravenously. Blood samples were drawn from individual groups of primates …